Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF – Get Rating) – Jefferies Financial Group lifted their Q3 2022 EPS estimates for Swedish Orphan Biovitrum AB (publ) in a research report issued to clients and investors on Wednesday, June 15th. Jefferies Financial Group analyst E. Yang now anticipates that the company will earn $0.11 per share for the quarter, up from their previous estimate of $0.09. The consensus estimate for Swedish Orphan Biovitrum AB (publ)’s current full-year earnings is $0.81 per share. Jefferies Financial Group also issued estimates for Swedish Orphan Biovitrum AB (publ)’s FY2022 earnings at $0.79 EPS, FY2024 earnings at $1.50 EPS, FY2025 earnings at $1.97 EPS and FY2026 earnings at $1.81 EPS.
Several other analysts also recently issued reports on the stock. DNB Markets raised shares of Swedish Orphan Biovitrum AB (publ) from a “hold” rating to a “buy” rating in a report on Thursday, April 14th. Barclays upped their price target on shares of Swedish Orphan Biovitrum AB (publ) from SEK 210 to SEK 215 in a report on Tuesday, February 22nd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $215.00.
Swedish Orphan Biovitrum AB (publ) Company Profile (Get Rating)
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.
- Get a free copy of the StockNews.com research report on Swedish Orphan Biovitrum AB (publ) (BIOVF)
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
- The Analysts Upgrade… Retail Stocks?
- Dividend Stocks and Your Roth IRA
- The Q2 Earnings Season Could Be A Bloodbath
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Swedish Orphan Biovitrum AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.